Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients

Critical Care Medicine

Volumn 42, Issue 5, 2014, Pages 1081-1088

  Lee, Hao Yuan ^a,b   Chen, Chyi Liang ^b   Wu, Si Ru ^b   Huang, Chih Wei ^b   Chiu, Cheng Hsun ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii complex; bacteremia; imipenem resistance; outcome; risk factor

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEMASE; CEFEPIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; RNA 16S; RNA 23S; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CRITICALLY ILL PATIENT; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; RISK FACTOR; RNA SEQUENCE; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; CRITICAL ILLNESS; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HUMANS; IMIPENEM; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA, VENTILATOR-ASSOCIATED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, RIBOSOMAL, 16S; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84899586272     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000125     Document Type: Article

References (35)

1. Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317
2. Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-582
3. Lee YT, Kuo SC, Yang SP, et al: Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: Relation to severity of infection. Clin Infect Dis 2012; 55:209-215
4. Chuang YC, Sheng WH, Li SY, et al: Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 2011; 52:352-360
5. Kuo SC, Lee YT, Yang SP, et al: Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia. Clin Microbiol Infect 2013; 19:634-639
6. Chuang YC, Chang SC, Wang WK: High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: Implication for pathogenesis and evaluation of therapy. PLoS One 2010; 5:e14133
7. Kwon KT, Oh WS, Song JH, et al: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59:525-530
8. Erbay A, Idil A, Gözel MG, et al: Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34:575-579
9. Sheng WH, Liao CH, Lauderdale TL, et al: A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010; 14:e764-e769
10. Falagas ME, Kasiakou SK, Rafailidis PI, et al: Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57:1251-1254
11. Lee YC, Huang YT, Tan CK, et al: Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: Comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011; 66:1839-1846
12. Falagas ME, Rafailidis PI: Attributable mortality of Acinetobacter baumannii: No longer a controversial issue. Crit Care 2007; 11:134
13. Chiang MC, Kuo SC, Chen SJ, et al: Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012; 40:19-26
14. Routsi C, Pratikaki M, Platsouka E, et al: Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: Risk factors, clinical features and outcomes. Infection 2010; 38:173-180
15. Chang HC, Wei YF, Dijkshoorn L, et al: Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol 2005; 43:1632-1639
16. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement. Document M100-S20. Wayne, PA, CLSI, 2010
17. Ye JJ, Huang CT, Shie SS, et al: Multidrug resistant Acinetobacter baumannii: Risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010; 5:e9947
18. Lee HY, Chang RC, Su LH, et al: Wide spread of Tn2006 in an AbaR4-type resistance island among carbapenem-resistant Acinetobacter baumannii clinical isolates in Taiwan. Int J Antimicrob Agents 2012; 40:163-167
19. Bonten MJ, Kollef MH, Hall JB: Risk factors for ventilator-associated pneumonia: From epidemiology to patient management. Clin Infect Dis 2004; 38:1141-1149
20. Bekaert M, Timsit JF, Vansteelandt S, et al; Outcomerea Study Group: Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis. Am J Respir Crit Care Med 2011; 184:1133-1139
21. Corvec S, Poirel L, Naas T, et al: Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 1530-1533
22. Chen TL, Wu RC, Shaio MF, et al: Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52:2573-2580
23. Lee HY, Chen CL, Wang SB, et al: Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: Mechanism and clinical implications. Int J Antimicrob Agents 2011; 37:302-308
24. Turton JF, Baddal B, Perry C: Use of the accessory genome for characterization and typing of Acinetobacter baumannii. J Clin Microbiol 2011; 49:1260-1266
25. Hamidian M, Hall RM: AbaR4 replaces AbaR3 in a carbapenem-resistant Acinetobacter baumannii isolate belonging to global clone 1 from an Australian hospital. J Antimicrob Chemother 2011; 66:2484-2491
26. Peleg AY, Potoski BA, Rea R, et al: Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother 2007; 59:128-131
27. Tenover FC, Arbeit RD, Goering RV, et al: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-2239
28. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
29. Chuang YC, Chang SC, Wang WK: Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia. Crit Care Med 2012; 40:2273-2280
30. Lee SO, Kim NJ, Choi SH, et al: Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrob Agents Chemother 2004; 48:224-228
31. Zhou Z, Du X, Wang L, et al: Clinical carbapenem-resistant Acinetobacter baylyi strain coharboring blaSIM-1 and blaOXA-23 from China. Antimicrob Agents Chemother 2011; 55:5347-5349
32. Bonnin RA, Ocampo-Sosa AA, Poirel L, et al: Biochemical and genetic characterization of carbapenem-hydrolyzing β-lactamase OXA-229 from Acinetobacter bereziniae. Antimicrob Agents Chemother 2012; 56:3923-3927
33. Kim DH, Choi JY, Jung SI, et al: AbaR4-type resistance island including the blaOXA-58 gene in Acinetobacter nosocomialis isolates. Antimicrob Agents Chemother 2012; 56:4548-4549
34. Lee YT, Huang LY, Chiang DH, et al: Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009; 34:580-584
35. Chen TL, Lee YT, Kuo SC, et al: Emergence and distribution of plasmids bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. Antimicrob Agents Chemother 2010; 54:4575-4581